Skip to main content

Advertisement

SpringerLink
Log in

Study of ATP borate ester effects on cell sensitization to radiation emitted by a nuclear reactor

  • Published:
Nuclear Science and Techniques Aims and scope Submit manuscript

Abstract

Adenosine triphosphate (ATP) borate ester as a new boron agent for boron neutron capture therapy was tested. It was synthesized via a dehydration reaction induced by heating adenosine triphosphate disodium with boric acid. Next, ATP borate ester pretreatments were assessed to study their effects on cell sensitization from exposure to thermal neutron irradiation emitted by a nuclear reactor. Using cell viability assays (CCK8), survival rates of A549 cells pretreated with or without boron-containing agents, including ATP borate ester and 4-dihydroxyborylphenylalanine (BPA), were measured. One week after feeding an ATP borate ester solution to tumor-bearing nude mice, elemental B content values of tumor muscle and blood were measured using inductively coupled plasma mass spectrometry (ICP-MS). Meanwhile, other tumor tissue samples were placed in a culture medium, subjected to a 3-min neutron irradiation exposure, and then fixed in formalin 24 h later for the terminal-deoxynucleotidyl transferase (TDT)-mediated dUTP nick end labeling (TUNEL) immunohistochemical staining analysis. Results showed that A549 cell irradiation sensitization (irradiation dose of 0.33 Gy) varied with pretreatment. Sensitization values of the ATP borate ester pretreatment group were 1.3–14.1 with boron agent concentrations of 0.3–4.5 mM. Within 1.1–3.4 mM, ATP borate ester showed significantly higher sensitization values than BPA. Meanwhile, TUNEL results demonstrated that apoptosis rates of tumor tissue cells exposed to irradiation after ATP borate ester pretreatment significantly exceeded the corresponding rates for BPA-pretreated cells. In animal experiments, although the distribution ratio of ATP borate ester (tumor tissue/normal muscle, T/N) of 1.2 was not significantly different compared with that of BPA (1.3), the total ATP borate ester concentration in the tumor tissue (0.79 ± 0.05 μg/g) significantly exceeded that of BPA (0.58 ± 0.05 μg/g). Thus, compared with BPA, the greater enrichment of ATP borate ester in tumor tissues permits preferential targeting toward tumor cells for radiation sensitization. Therefore, ATP borate ester is superior to BPA for use in boron neutron capture therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

References

  1. A. Malik, M. Sultana, A. Qazi et al., Role of natural radiosensitizers and cancer cell radioresistance: an update. Anal. Cell. Pathol. (Amst.) 2016, 6146595 (2016). https://doi.org/10.1155/2016/6146595

    Article  Google Scholar 

  2. R. Baskar, J.W. Dai, W.L. Nei et al., Biological response of cancer cells to radiation treatment. Front. Mol. Biosci. 1, 24 (2014). https://doi.org/10.3389/fmolb.2014.00024

    Article  Google Scholar 

  3. S.Y. Lee, E.K. Jeong, M.K. Ju et al., Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol. Cancer 16, 10 (2017). https://doi.org/10.1186/s12943-016-0577-4

    Article  Google Scholar 

  4. J. Shen, L.F. Wang, Z.Y. Zou et al., Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J. Gastroenterol. 23, 5395–5404 (2017). https://doi.org/10.3748/wjg.v23.i29.5395

    Article  Google Scholar 

  5. T. Sun, Y.Y. Li, Y.L. Huang et al., Targeting glioma stem cells enhances anti-tumor effect of boron neutron capture therapy. Oncotarget 7, 43095–43108 (2016). https://doi.org/10.18632/oncotarget.9355

    Article  Google Scholar 

  6. J.W. Hopewell, G.M. Morris, A. Schwint et al., The radiobiological principles of boron neutron capture therapy: a critical review. Appl. Radiat. Isot. 69, 1756–1759 (2011). https://doi.org/10.1016/j.apradiso.2011.04.019

    Article  Google Scholar 

  7. A.B. Volovetsky, V.S. Sukhov, I.V. Balalaeva et al., Pharmacokinetics of chlorin e(6)-cobalt bis(dicarbollide) conjugate in Balb/c mice with engrafted carcinoma. Int. J. Mol. Sci. 18, 2556 (2017). https://doi.org/10.3390/ijms18122556

    Article  Google Scholar 

  8. N. Kuthala, R. Vankayala, Y.N. Li et al., Engineering novel targeted boron-10-enriched theranostic nanomedicine to combat against murine brain tumors via MR imaging-guided boron neutron capture therapy. Adv. Mater. 29, 110–120 (2017). https://doi.org/10.1002/adma.201700850

    Article  Google Scholar 

  9. P.J. Kueffer, C.A. Maitz, A.A. Khan et al., Boron neutron capture therapy demonstrated in mice bearing EMT6 tumors following selective delivery of boron by rationally designed liposomes. Proc. Natl. Acad. Sci. U.S.A. 110, 6512–6517 (2013). https://doi.org/10.1073/pnas.1303437110

    Article  Google Scholar 

  10. G. Choi, I.R. Jeon, H. Piao et al., Highly condensed boron cage cluster anions in 2D carrier and its enhanced antitumor efficiency for boron neutron capture therapy. Adv. Funct. Mater. 28, 1704470 (2018). https://doi.org/10.1002/adfm.201704470

    Article  Google Scholar 

  11. L.W. Wang, Y.W. Chen, C.Y. Ho et al., Fractionated boron neutron capture therapy in locally recurrent head and neck cancer: a prospective phase I/II Trial. Int. J. Radiat. Oncol. 95, 396–403 (2016). https://doi.org/10.1016/j.ijrobp.2016.02.028

    Article  Google Scholar 

  12. R.F. Barth, M.G. Vicente, O.K. Harling et al., Current status of boron neutron capture therapy of highgrade gliomas and recurrent head and neck cancer. Radiat. Oncol. 29, 146–147 (2012). https://doi.org/10.1186/1748-717X-7-146

    Article  Google Scholar 

  13. M.A. Garabalino, E.M. Heber, A.M. Hughes et al., Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model. Radiat. Environ. Biophys. 52, 351–361 (2013). https://doi.org/10.1007/s00411-013-0467-8

    Article  Google Scholar 

  14. Z.Y. Gao, Y. Horiguchi, K. Nakai et al., Use of boron cluster-containing redox nanoparticles with ROS scavenging ability in boron neutron capture therapy to achieve high therapeutic efficiency and low adverse effects. Biomaterials 104, 201–212 (2016). https://doi.org/10.1016/j.biomaterials.2016.06.046

    Article  Google Scholar 

  15. K. Sköld, B.H. Stenstam, A.Z. Diaz et al., Boron neutron capture therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f. Acta Neurol. Scand. 122, 58–62 (2010). https://doi.org/10.1111/j.1600-0404.2009.01267.x

    Article  Google Scholar 

  16. W. Yang, G. Wu, R.F. Barth et al., Molecular targeting and treatment of composite EGFR and EGFRvIII -positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 14, 883–891 (2008). https://doi.org/10.1158/1078-0432.CCR-07-1968

    Article  Google Scholar 

  17. C. Achilli, S. Grandi, A. Ciana et al., Biocompatibility of functionalized boron phosphate (BPO4) nanoparticles for boron neutron capture therapy (BNCT) application. Nanomedicine: NBM 10, 589–597 (2014). https://doi.org/10.1016/j.nano.2013.10.003

    Article  Google Scholar 

  18. H.J. Xiong, X. Wei, D.F. Zhou et al., Amphiphilic Polycarbonates from Carborane-installed cyclic carbonates as potential agents for boron neutron capture therapy. Bioconjugate Chem. 27, 2214–2223 (2016). https://doi.org/10.1021/acs.bioconjchem.6b00454

    Article  Google Scholar 

  19. R. Hiramatsu, S. Kawabata, S. Miyatake et al., Application of a novel boronated porphyrin (H2OCP) as a dual sensitizer for both PDT and BNCT. Lasers Surg. Med. 43, 52–58 (2011). https://doi.org/10.1002/lsm.21026

    Article  Google Scholar 

  20. S. Narayanasamy, B.T.S. Thirumamagal, J. Johnsamuel et al., Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer. Bioorgan. Med. Chem. 14, 6886–6899 (2006). https://doi.org/10.1016/j.bmc.2006.06.039

    Article  Google Scholar 

  21. S.M. Lato, N.D.S. Ozerova, K.Z. He et al., Boron-containing aptamers to ATP. Nucleic Acids Res. 30, 1401–1407 (2002). https://doi.org/10.1093/nar/30.6.1401

    Article  Google Scholar 

  22. A.N. Lane, T.W.M. Fan, Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 43, 2466–2485 (2015). https://doi.org/10.1093/nar/gkv047

    Article  Google Scholar 

  23. Y.P. Tong, C.L. Huang, J.F. Zhang, A novel EGFR-TKI inhibitor (cAMP-H3BO3 complex) combined with thermal therapy is a promising strategy to improve lung cancer treatment outcomes. Oncotarget 8, 56327–56337 (2017). https://doi.org/10.18632/oncotarget.17628

    Article  Google Scholar 

  24. H. Zarredar, S. Pashapour, K. Ansarin et al., Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro. J. Cell. Physiol. 234, 1560–1566 (2019). https://doi.org/10.1002/jcp.27021

    Article  Google Scholar 

  25. Y.L. Yao, L.S. Zhou, W.F. Liao et al., HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway. Carbohydr. Polym. 204, 111–123 (2019). https://doi.org/10.1016/j.carbpol.2018.10.008

    Article  Google Scholar 

  26. D. Kaniowski, E.O. Katarzyna, M. Sobczak et al., High boron-loaded DNA-oligomers as potential boron neutron capture therapy and antisense oligonucleotide dual-action anticancer agents. Molecules 22, 1393 (2017). https://doi.org/10.3390/molecules22091393

    Article  Google Scholar 

  27. J. Fang, H. Nakamura, H. Maeda, The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63, 136–151 (2011). https://doi.org/10.1016/j.addr.2010.04.009

    Article  Google Scholar 

  28. D. Alberti, N. Protti, A. Toppino et al., A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of boron neutron capture therapy in the lung cancer treatment. Nanomedicine: NBM 11, 741–750 (2015). https://doi.org/10.1016/j.nano.2014.12.004

    Article  Google Scholar 

  29. H.J. Xiong, D.F. Zhou, Y.X. Qi et al., Doxorubicin-loaded carborane-conjugated polymeric nanoparticles as delivery system for combination cancer therapy. Biomacromol 16, 3980–3988 (2015). https://doi.org/10.1021/acs.biomac.5b01311

    Article  Google Scholar 

  30. R. Yahyapour, E. Motevaseli, A. Rezaeyan et al., Mechanisms of radiation bystander and non-targeted effects: implications to radiation carcinogenesis and radiotherapy. Curr. Radiopharm. 11, 34–45 (2018). https://doi.org/10.2174/1874471011666171229123130

    Article  Google Scholar 

  31. M.T. Islam, Radiation interactions with biological systems. Int. J. Radiat. Biol. 93, 487–493 (2017). https://doi.org/10.1080/09553002.2017.1286050

    Article  Google Scholar 

  32. Y.P. Tong, S.M. Li, C.L. Huang, EGFR induces DNA decomposition via phosphodiester bond cleavage. Sci. Res. 7, 43698 (2017). https://doi.org/10.1038/srep43698

    Article  Google Scholar 

  33. Z.J. Lesnikowski, R.F. Schinazi, Carboranyl oligonucleotides. 1. Synthesis of thymidine (3′,5′) thymidine (o-carboran-1-ylmethyl) phosphonate. J. Org. Chem. 58, 6531–6534 (1993). https://doi.org/10.1021/jo00076a001

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Physics and Optoelectronic Engineering, Shenzhen University, Nanhai Avenue 3688, Shenzhen, 518060, China

    Miao Wang, Yong-Peng Tong, Qi Luo & Shi-Peng Hu

Authors
  1. Miao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong-Peng Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qi Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shi-Peng Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong-Peng Tong.

Additional information

This work was supported by the project, “Research on the targeted treatment of malignant tumors with Base 20180199 New Transmembrane Antibody” (No. JCYJ20180507182217748) and the National Natural Science Foundation of China (No. 11375117). The study was approved by the animal ethics committee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, M., Tong, YP., Luo, Q. et al. Study of ATP borate ester effects on cell sensitization to radiation emitted by a nuclear reactor. NUCL SCI TECH 31, 2 (2020). https://doi.org/10.1007/s41365-019-0713-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s41365-019-0713-0

Keywords

Search

Navigation